Apricoxib
![]()  | |
| Identifiers | |
|---|---|
  | |
| CAS Number | 162011-90-7 | 
| PubChem (CID) | 9820073 | 
| ChemSpider | 7995822 | 
| Chemical and physical data | |
| Formula | C19H20N2O3S | 
| Molar mass | 356.4387 g/mol | 
| 3D model (Jmol) | Interactive image | 
  | |
  | |
Apricoxib is an experimental anticancer drug in Phase II clinical trials. It is a COX-2 inhibitor which improves standard therapy response in molecularly defined models of pancreatic cancer.[1]
See also
References
- ↑ Kirane, A. (2012). "Apricoxib, a Novel Inhibitor of COX-2, Markedly Improves Standard Therapy Response in Molecularly Defined Models of Pancreatic Cancer". Clinical Cancer Research. 18 (18): 5031–5042. doi:10.1158/1078-0432.CCR-12-0453.
 
This article is issued from Wikipedia - version of the 4/5/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.
